THE TALK: Gastrointestinal Cancers A Review of Data from the ESMO 2021 Virtual Meeting - Episode 2

ESMO 2021 Updates in Gastroesophageal and Gastric Adenocarcinomas

, , ,

Drs Sam Klempner, Nataliya V. Uboha, Daniel H. Ahn, and Manish A. Shah discuss recent data presented at ESMO 2021 for metastatic or locally advanced gastroesophageal and gastric adenocarcinomas.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: ESMO 2021 Updates in Metastatic Esophageal Squamous Cell Carcinoma
    Now Viewing
    EP. 2: ESMO 2021 Updates in Gastroesophageal and Gastric Adenocarcinomas
    EP. 3: ESMO 2021 Updates in HER2+ Metastatic Gastric and Gastroesophageal Cancer
    EP. 4: ESMO 2021 Updates in Gastric Cancer and Colorectal Cancer

    Data from the following clinical trials are discussed:

    • LBA7 - Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study (Checkmate 649)
    • LBA53 - Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase 3 study (ORIENT-16)
    • 1758O - Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency
    x